BRISTOL-MYERS SQUIBB COMPANY Research and Development Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Research and Development Expense of $2.96 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for the quarter ending 2026-06-30 was $2.96B, a 14.69% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for the quarter ending 2026-03-31 was $2.65B, a 17.37% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for the quarter ending 2025-12-31 was $2.59B, a 18.96% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for the quarter ending 2025-09-30 was $2.53B, a 6.49% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for fiscal 2025 was $9.95B, a 10.83% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for fiscal 2024 was $11.16B, a 20.00% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for fiscal 2023 was $9.30B, a 2.21% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY research and development expense for fiscal 2022 was $9.51B, a 6.73% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.96B 10-Q · filed 2026-07-30 | $5.61B 10-Q · filed 2026-07-30 | $8.19B derived: sum of 3 quarters · filed 2026-07-30 | $10.72B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $2.65B 10-Q · filed 2026-04-30 | $5.24B derived: sum of 2 quarters · filed 2026-04-30 | $7.76B derived: sum of 3 quarters · filed 2026-04-30 | $10.34B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $2.59B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.11B derived: sum of 2 quarters · filed 2026-02-11 | $7.69B derived: sum of 3 quarters · filed 2026-07-30 | $9.95B 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $2.53B 10-Q · filed 2025-10-30 | $5.11B derived: sum of 2 quarters · filed 2026-07-30 | $7.37B 10-Q · filed 2025-10-30 | $10.56B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $2.58B 10-Q · filed 2026-07-30 | $4.84B 10-Q · filed 2026-07-30 | $8.03B derived: sum of 3 quarters · filed 2026-07-30 | $10.40B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $2.26B 10-Q · filed 2026-04-30 | $5.45B derived: sum of 2 quarters · filed 2026-04-30 | $7.82B derived: sum of 3 quarters · filed 2026-04-30 | $10.72B derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $3.19B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.57B derived: sum of 2 quarters · filed 2026-02-11 | $8.46B derived: sum of 3 quarters · filed 2026-02-11 | $11.16B 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $2.37B 10-Q · filed 2025-10-30 | $5.27B derived: sum of 2 quarters · filed 2025-10-30 | $7.97B 10-Q · filed 2025-10-30 | $10.45B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $2.90B 10-Q · filed 2025-07-31 | $5.59B 10-Q · filed 2025-07-31 | $8.07B derived: sum of 3 quarters · filed 2026-02-11 | $10.31B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $2.69B 10-Q · filed 2025-04-24 | $5.17B derived: sum of 2 quarters · filed 2026-02-11 | $7.42B derived: sum of 3 quarters · filed 2026-02-11 | $9.67B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $2.48B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $4.72B derived: sum of 2 quarters · filed 2026-02-11 | $6.98B derived: sum of 3 quarters · filed 2026-02-11 | $9.30B 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $2.24B 10-Q · filed 2024-10-31 | $4.50B derived: sum of 2 quarters · filed 2024-10-31 | $6.82B 10-Q · filed 2024-10-31 | $9.33B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | $2.26B 10-Q · filed 2024-07-26 | $4.58B 10-Q · filed 2024-07-26 | $7.09B derived: sum of 3 quarters · filed 2025-02-12 | $9.51B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $2.32B 10-Q · filed 2024-04-25 | $4.83B derived: sum of 2 quarters · filed 2025-02-12 | $7.25B derived: sum of 3 quarters · filed 2025-02-12 | $9.57B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $2.51B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.93B derived: sum of 2 quarters · filed 2025-02-12 | $7.25B derived: sum of 3 quarters · filed 2025-02-12 | $9.51B 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $2.42B 10-Q · filed 2023-10-26 | $4.74B derived: sum of 2 quarters · filed 2023-10-26 | $7.00B 10-Q · filed 2023-10-26 | $9.52B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $2.32B 10-Q · filed 2023-07-27 | $4.58B 10-Q · filed 2023-07-27 | $7.10B derived: sum of 3 quarters · filed 2024-02-13 | $10.08B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | $2.26B 10-Q · filed 2023-04-27 | $4.78B derived: sum of 2 quarters · filed 2024-02-13 | $7.76B derived: sum of 3 quarters · filed 2024-02-13 | $10.24B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | $2.52B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $5.50B derived: sum of 2 quarters · filed 2024-02-13 | $7.98B derived: sum of 3 quarters · filed 2024-02-13 | $10.20B 10-K · filed 2024-02-13 | $11.35B 10-K · filed 2022-02-09 | |||
| 2021-09-30 | $2.98B 10-Q · filed 2022-10-26 | $3.25B 10-Q · filed 2021-10-27 | $5.46B derived: sum of 2 quarters · filed 2022-10-26 | $7.68B 10-Q · filed 2022-10-26 | $8.75B 10-Q · filed 2021-10-27 | $10.33B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-06-30 | $2.48B 10-Q · filed 2022-07-27 | $3.27B 10-Q · filed 2021-07-28 | $4.70B 10-Q · filed 2022-07-27 | $5.50B 10-Q · filed 2021-07-28 | $7.35B derived: sum of 3 quarters · filed 2023-02-14 | $9.85B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-03-31 | $2.22B 10-Q · filed 2022-04-29 | $2.23B 10-Q · filed 2021-04-29 | $4.87B derived: sum of 2 quarters · filed 2023-02-14 | $7.37B derived: sum of 3 quarters · filed 2023-02-14 | $9.89B derived: sum of 4 quarters · filed 2023-02-14 | |||
| 2020-12-31 | $2.65B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $5.15B derived: sum of 2 quarters · filed 2023-02-14 | $7.68B derived: sum of 3 quarters · filed 2023-02-14 | $10.05B 10-K · filed 2023-02-14 | $11.14B 10-K · filed 2021-02-10 | |||
| 2020-09-30 | $2.50B 10-Q · filed 2021-10-27 | $5.02B derived: sum of 2 quarters · filed 2021-10-27 | $7.39B 10-Q · filed 2021-10-27 | $9.49B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $2.52B 10-Q · filed 2021-07-28 | $4.89B 10-Q · filed 2021-07-28 | $6.99B derived: sum of 3 quarters · filed 2022-02-09 | $8.37B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $2.37B 10-Q · filed 2021-04-29 | $4.47B derived: sum of 2 quarters · filed 2022-02-09 | $5.85B derived: sum of 3 quarters · filed 2022-02-09 | $7.17B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $2.10B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $3.48B derived: sum of 2 quarters · filed 2022-02-09 | $4.80B derived: sum of 3 quarters · filed 2022-02-09 | $6.15B 10-K · filed 2022-02-09 | ||||
| 2019-09-30 | $1.38B 10-Q · filed 2020-11-05 | $1.38B 10-Q · filed 2019-10-31 | $2.70B derived: sum of 2 quarters · filed 2020-11-05 | $4.05B 10-Q · filed 2020-11-05 | $4.06B 10-Q · filed 2019-10-31 | $5.42B derived: sum of 4 quarters · filed 2021-02-10 | ||
| 2019-06-30 | $1.32B 10-Q · filed 2020-08-06 | $1.33B 10-Q · filed 2019-07-25 | $2.67B 10-Q · filed 2020-08-06 | $2.68B 10-Q · filed 2019-07-25 | $4.04B derived: sum of 3 quarters · filed 2021-02-10 | $5.32B derived: sum of 4 quarters · filed 2021-02-10 | ||
| 2019-03-31 | $1.35B 10-Q · filed 2020-05-07 | $1.35B 10-Q · filed 2019-04-25 | $2.71B derived: sum of 2 quarters · filed 2021-02-10 | $4.00B derived: sum of 3 quarters · filed 2021-02-10 | $6.43B derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2018-12-31 | $1.37B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $2.65B derived: sum of 2 quarters · filed 2021-02-10 | $5.08B derived: sum of 3 quarters · filed 2021-02-10 | $6.33B 10-K · filed 2021-02-10 | $6.34B 10-K · filed 2019-02-25 | |||
| 2018-09-30 | $1.28B 10-Q · filed 2019-10-31 | $3.71B derived: sum of 2 quarters · filed 2019-10-31 | $4.96B 10-Q · filed 2019-10-31 | $6.89B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $2.44B 10-Q · filed 2019-07-25 | $3.69B 10-Q · filed 2019-07-25 | $5.61B derived: sum of 3 quarters · filed 2020-02-24 | $7.17B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $1.25B 10-Q · filed 2019-04-25 | $3.17B derived: sum of 2 quarters · filed 2020-02-24 | $4.74B derived: sum of 3 quarters · filed 2020-02-24 | $6.42B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $1.93B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $3.49B derived: sum of 2 quarters · filed 2020-02-24 | $5.17B derived: sum of 3 quarters · filed 2020-02-24 | $6.47B 10-K · filed 2020-02-24 | $6.41B 10-K · filed 2018-02-13 | |||
| 2017-09-30 | $1.56B 10-Q · filed 2018-10-25 | $1.54B 10-Q · filed 2017-10-26 | $3.24B derived: sum of 2 quarters · filed 2018-10-25 | $4.54B 10-Q · filed 2018-10-25 | $4.49B 10-Q · filed 2017-10-26 | $6.01B derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-06-30 | $1.68B 10-Q · filed 2018-07-26 | $1.66B 10-Q · filed 2017-07-27 | $2.98B 10-Q · filed 2018-07-26 | $2.95B 10-Q · filed 2017-07-27 | $4.45B derived: sum of 3 quarters · filed 2019-02-25 | $5.59B derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-03-31 | $1.30B 10-Q · filed 2018-04-26 | $1.29B 10-Q · filed 2017-04-27 | $2.77B derived: sum of 2 quarters · filed 2019-02-25 | $3.91B derived: sum of 3 quarters · filed 2019-02-25 | $5.18B derived: sum of 4 quarters · filed 2019-02-25 | |||
| 2016-12-31 | $1.47B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $2.61B derived: sum of 2 quarters · filed 2019-02-25 | $3.88B derived: sum of 3 quarters · filed 2019-02-25 | $5.01B 10-K · filed 2019-02-25 | $4.94B 10-K · filed 2017-02-21 | |||
| 2016-09-30 | $1.14B 10-Q · filed 2017-10-26 | $2.40B derived: sum of 2 quarters · filed 2017-10-26 | $3.54B 10-Q · filed 2017-10-26 | $5.46B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | $1.27B 10-Q · filed 2017-07-27 | $2.40B 10-Q · filed 2017-07-27 | $4.32B derived: sum of 3 quarters · filed 2018-02-13 | $5.45B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | $1.14B 10-Q · filed 2017-04-27 | $3.05B derived: sum of 2 quarters · filed 2018-02-13 | $4.18B derived: sum of 3 quarters · filed 2018-02-13 | $6.04B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | $1.92B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $3.05B derived: sum of 2 quarters · filed 2018-02-13 | $4.90B derived: sum of 3 quarters · filed 2018-02-13 | $5.92B 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | $1.13B 10-Q · filed 2016-10-27 | $2.99B derived: sum of 2 quarters · filed 2016-10-27 | $4.00B 10-Q · filed 2016-10-27 | $5.19B derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-06-30 | $1.86B 10-Q · filed 2016-07-28 | $2.87B 10-Q · filed 2016-07-28 | $4.06B derived: sum of 3 quarters · filed 2017-02-21 | $5.04B derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-03-31 | $1.02B 10-Q · filed 2016-04-28 | $2.21B derived: sum of 2 quarters · filed 2017-02-21 | $3.19B derived: sum of 3 quarters · filed 2017-02-21 | $4.60B derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2014-12-31 | $1.19B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $2.17B derived: sum of 2 quarters · filed 2017-02-21 | $3.59B derived: sum of 3 quarters · filed 2017-02-21 | $4.53B 10-K · filed 2017-02-21 | ||||
| 2014-09-30 | $983.00M 10-Q · filed 2015-10-27 | $2.40B derived: sum of 2 quarters · filed 2015-10-27 | $3.35B 10-Q · filed 2015-10-27 | $4.30B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-06-30 | $1.42B 10-Q · filed 2015-07-23 | $2.36B 10-Q · filed 2015-07-23 | $3.32B derived: sum of 3 quarters · filed 2016-02-12 | $4.21B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-03-31 | $946.00M 10-Q · filed 2015-04-28 | $1.90B derived: sum of 2 quarters · filed 2016-02-12 | $2.80B derived: sum of 3 quarters · filed 2016-02-12 | $3.75B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2013-12-31 | $957.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.85B derived: sum of 2 quarters · filed 2016-02-12 | $2.80B derived: sum of 3 quarters · filed 2016-02-12 | $3.73B 10-K · filed 2016-02-12 | ||||
| 2013-09-30 | $893.00M 10-Q · filed 2014-10-24 | $1.84B derived: sum of 2 quarters · filed 2014-10-24 | $2.77B 10-Q · filed 2014-10-24 | $3.86B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-06-30 | $951.00M 10-Q · filed 2014-07-24 | $1.88B 10-Q · filed 2014-07-24 | $2.96B derived: sum of 3 quarters · filed 2015-02-13 | $3.91B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-03-31 | $930.00M 10-Q · filed 2014-04-29 | $2.01B derived: sum of 2 quarters · filed 2015-02-13 | $2.96B derived: sum of 3 quarters · filed 2015-02-13 | $3.92B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | $1.08B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $2.03B derived: sum of 2 quarters · filed 2015-02-13 | $3.00B derived: sum of 3 quarters · filed 2015-02-13 | $3.90B 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | $951.00M 10-Q · filed 2013-10-23 | $1.91B derived: sum of 2 quarters · filed 2013-10-23 | $2.82B 10-Q · filed 2013-10-23 | $3.83B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2012-06-30 | $962.00M 10-Q · filed 2013-07-25 | $1.87B 10-Q · filed 2013-07-25 | $2.88B derived: sum of 3 quarters · filed 2014-02-14 | $3.85B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2012-03-31 | $909.00M 10-Q · filed 2013-04-25 | $1.92B derived: sum of 2 quarters · filed 2014-02-14 | $2.89B derived: sum of 3 quarters · filed 2014-02-14 | $3.81B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2011-12-31 | $1.01B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $1.98B derived: sum of 2 quarters · filed 2014-02-14 | $2.90B derived: sum of 3 quarters · filed 2014-02-14 | $3.84B 10-K · filed 2014-02-14 | ||||
| 2011-09-30 | $973.00M 10-Q · filed 2012-10-24 | $1.90B derived: sum of 2 quarters · filed 2012-10-24 | $2.83B 10-Q · filed 2012-10-24 | $3.84B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $923.00M 10-Q · filed 2012-07-25 | $1.86B 10-Q · filed 2012-07-25 | $2.87B derived: sum of 3 quarters · filed 2013-02-15 | $3.69B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $935.00M 10-Q · filed 2012-04-26 | $1.95B derived: sum of 2 quarters · filed 2013-02-15 | $2.77B derived: sum of 3 quarters · filed 2013-02-15 | $3.59B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $1.01B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $1.83B derived: sum of 2 quarters · filed 2013-02-15 | $2.66B derived: sum of 3 quarters · filed 2013-02-15 | $3.57B 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $824.00M 10-Q · filed 2011-10-27 | $1.65B derived: sum of 2 quarters · filed 2011-10-27 | $2.56B 10-Q · filed 2011-10-27 | $3.66B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2010-06-30 | $822.00M 10-Q · filed 2011-07-28 | $1.73B 10-Q · filed 2011-07-28 | $2.84B derived: sum of 3 quarters · filed 2012-02-17 | $3.66B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2010-03-31 | $910.00M 10-Q · filed 2011-04-28 | $2.02B derived: sum of 2 quarters · filed 2012-02-17 | $2.84B derived: sum of 3 quarters · filed 2012-02-17 | $3.65B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2009-12-31 | $1.11B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $1.93B derived: sum of 2 quarters · filed 2012-02-17 | $2.74B derived: sum of 3 quarters · filed 2012-02-17 | $3.65B 10-K · filed 2012-02-17 | ||||
| 2009-09-30 | $820.00M 10-Q · filed 2010-10-26 | $838.00M 10-Q · filed 2009-10-22 | $1.63B derived: sum of 2 quarters · filed 2010-10-26 | $2.54B 10-Q · filed 2010-10-26 | $2.59B 10-Q · filed 2009-10-22 | $3.61B derived: sum of 4 quarters · filed 2011-02-18 | ||
| 2009-06-30 | $811.00M 10-Q · filed 2010-07-22 | $829.00M 10-Q · filed 2009-07-23 | $1.72B 10-Q · filed 2010-07-22 | $1.75B 10-Q · filed 2009-07-23 | $2.79B derived: sum of 3 quarters · filed 2011-02-18 | $3.62B derived: sum of 4 quarters · filed 2011-02-18 | ||
| 2009-03-31 | $908.00M 10-Q · filed 2010-04-29 | $1.98B derived: sum of 2 quarters · filed 2011-02-18 | $2.81B derived: sum of 3 quarters · filed 2011-02-18 | $3.64B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2008-12-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.90B derived: sum of 2 quarters · filed 2011-02-18 | $2.73B derived: sum of 3 quarters · filed 2011-02-18 | $3.51B 10-K · filed 2011-02-18 | ||||
| 2008-09-30 | $834.00M 10-Q · filed 2009-10-22 | $1.66B derived: sum of 2 quarters · filed 2009-10-22 | $2.44B 10-Q · filed 2009-10-22 | |||||
| 2008-06-30 | $826.00M 10-Q · filed 2009-07-23 | $1.61B 10-Q · filed 2009-07-23 | ||||||
| 2007-12-31 | $3.16B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |